. home.aspx

home.aspx
   

Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the dead

February 05, 2020 / NATALIE HEALEY

Despite halting development after disappointing trial findings in March, Biogen now plans to submit Alzheimer’s candidate aducanumab for FDA approval, after new analysis showed the drug just might work. Natalie Healey explores whether this high-profile comeback is justified. There had been such high hopes, but then the bad news came. Resuscitation was deemed futile; everyone was devastated. Then seven months later, something most surprising happened. A spectre appeared.